[Notes of caution]
This document is an English translation of the Japanese original. In the event of any differences or inconsistencies between the Japanese and English versions, the Japanese language version shall take precedence.

November 6, 2026

Consolidated Financial Results (Japanese Accounting Standards) for the Nine Months Ended September 30, 2026 (Q3 FY2026)

Listed company name: Ezaki Glico Co., Ltd. Listed stock exchange: Tokyo Stock Exchange
Securities Code: 2206 URL: https://www.glico.com/jp/
Representative: Katsuhisa Ezaki, Chairman
Scheduled date to commence dividend payments: -
Preparation of explanatory materials for financial results: Yes
Holding of a briefing on financial results: None

(Amounts less than ¥ million are rounded down.)

1. Consolidated Financial Results for the Nine Months Ended September 30, 2026 (January 1, 2026 to September 30, 2026)

(1) Consolidated results of operations

(The percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Nine months ended	¥ million	%	¥ million	%	¥ million	%	¥ million	%
September 30, 2026	281,008	6.1	8,246	(8.6)	11,056	1.7	7,719	6.2
September 30, 2025	264,736	9.8	9,020	(28.8)	10,869	(29.1)	7,268	(11.5)

(Note) Comprehensive Income: Nine months ended September 30, 2026: ¥8,582 million [48.5%]
Nine months ended September 30, 2025: ¥5,779 million [(44.9)%]

	Earnings per share (basic)	Earnings per share (diluted)
Nine months ended	¥	¥
September 30, 2026	124.96	-
September 30, 2025	114.18	-

(2) Consolidated financial position

	Total assets	Net assets	Shareholders' equity ratio
	¥ million	¥ million	%
As of September 30, 2026	372,995	258,218	69.0
As of December 31, 2025	394,129	278,532	70.5

(Reference) Shareholders' equity: As of September 30, 2026: ¥257,514 million
As of December 31, 2025: ¥277,904 million

2. Dividend Status

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	¥	¥	¥	¥	¥
Fiscal year ended December 31, 2025	-	45.00	-	50.00	95.00
Fiscal year ending December 31, 2026	-	45.00			
Fiscal year ending December 31, 2026 (Forecast)			-	50.00	95.00

(Note) Revisions to dividend forecasts published most recently: None

3. Consolidated Performance Forecasts for the Fiscal Year Ending December 31, 2026 (January 1, 2026 - December 31, 2026)

(The percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	¥ million	%	¥ million	%	¥ million	%	¥ million	%	¥
Full year	390,000	7.9	12,000	37.4	14,000	20.2	9,000	78.7	143.52

(Note) Revisions to financial forecasts published most recently: None

* Notes

(1) Transfers of important subsidiaries during fiscal period (transfers of designated subsidiaries incidental to changes in scope of consolidation): None
Newly included: None
Excluded: None

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: None

(3) Changes in accounting practices, changes in accounting estimates, retrospective restatements
(i) Changes in accounting practices due to a revision of accounting standards, etc.: None
(ii) Changes in accounting practices other than (i): None
(iii) Changes in accounting estimates: None
(iv) Retrospective restatements: None

(4) Number of shares issued (common stock)
(i) Number of shares issued as of term-end (including treasury shares)
As of September 30, 2026 68,468,569 shares
As of December 31, 2025 68,468,569 shares

(ii) Number of treasury shares as of term-end
As of September 30, 2026 9,021,516 shares
As of December 31, 2025 4,807,117 shares

(iii) Average number of shares during fiscal year
Nine months ended September 30, 2026 61,770,717 shares
Nine months ended September 30, 2025 63,663,319 shares

* Review of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: Yes (voluntary)

* Explanation of appropriate use of earnings projections, other explanatory notes
Earnings projections and other forward-looking statements indicated in these materials are based on information available at the time and on certain assumptions deemed reasonable at the time. These statements do not represent any guarantee of achievement by the Company. Furthermore, there is the possibility of significant changes in actual earnings due to various factors.

4. Quarterly Consolidated Financial Statements

(1) Quarterly Consolidated Balance Sheets

(Unit: ¥ million)

	As of December 31, 2025	As of September 30, 2026
Assets		
Current assets		
Cash and deposits	68,631	57,233
Notes and accounts receivable - trade	50,484	41,991
Merchandise and finished goods	21,243	25,053
Work in process	1,368	1,943
Raw materials and supplies	28,305	24,553
Other	10,512	10,524
Allowance for doubtful accounts	(157)	(187)
Total current assets	180,388	161,112
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	40,144	38,921
Machinery, equipment and vehicles, net	36,083	33,929
Tools, furniture and fixtures, net	6,325	6,213
Land	16,548	16,475
Leased assets, net	2,206	2,166
Construction in progress	3,972	4,348
Total property, plant and equipment	105,280	102,055
Intangible assets		
Software	22,943	19,022
Software in progress	673	1,013
Goodwill	1,337	1,004
Other	428	369
Total intangible assets	25,382	21,410
Investments and other assets		
Investment securities	55,822	61,168
Retirement benefit asset	9,229	9,309
Investment property, net	12,193	12,179
Other	5,878	5,804
Allowance for doubtful accounts	(45)	(45)
Total investments and other assets	83,078	88,417
Total non-current assets	213,741	211,883
Total assets	394,129	372,995

(Unit: ¥ million)

	As of December 31, 2025	As of September 30, 2026
Liabilities		
Current liabilities		
Notes and accounts payable - trade	44,268	35,120
Short-term borrowings	46	13,801
Accrued expenses	26,202	22,707
Income taxes payable	1,259	1,647
Refund liability	9,302	10,668
Provision for bonuses for directors (and other officers)	86	–
Provision for system failure response costs	355	–
Provision for product recall-related expenses	1,030	–
Other	12,700	9,949
Total current liabilities	95,252	93,896
Non-current liabilities		
Long-term borrowings	108	108
Retirement benefit liability	1,279	1,344
Deferred tax liabilities	12,659	12,969
Other	6,296	6,458
Total non-current liabilities	20,344	20,881
Total liabilities	115,597	114,777
Net assets		
Shareholders' equity		
Share capital	7,773	7,773
Capital surplus	7,230	7,230
Retained earnings	228,245	230,023
Treasury shares	(13,603)	(36,536)
Total shareholders' equity	229,646	208,490
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	18,178	21,446
Deferred gains or losses on hedges	671	42
Foreign currency translation adjustment	26,762	25,440
Remeasurements of defined benefit plans	2,645	2,094
Total accumulated other comprehensive income	48,257	49,024
Non-controlling interests	627	703
Total net assets	278,532	258,218
Total liabilities and net assets	394,129	372,995

(2) Quarterly Consolidated Statements of Income and Comprehensive Income

(Unit: ¥ million)

	Nine months ended September 30, 2025	Nine months ended September 30, 2026
Net sales	264,736	281,008
Cost of sales	164,867	175,864
Gross profit	99,868	105,144
Selling, general and administrative expenses		
Transportation and storage costs	22,324	22,083
Promotion expenses	9,461	11,664
Advertising expenses	10,959	11,100
Salaries and allowances	17,440	18,889
Retirement benefit expenses	(8)	(86)
Other	30,670	33,245
Total selling, general and administrative expenses	90,847	96,897
Operating profit	9,020	8,246
Non-operating income		
Interest income	549	471
Dividend income	436	469
Foreign exchange gains	–	197
Share of profit of entities accounted for using equity method	771	311
Subsidy income	702	998
Rental income from real estate	506	576
Other	865	1,145
Total non-operating income	3,831	4,170
Non-operating expenses		
Interest expenses	89	152
Donations	392	48
Foreign exchange losses	858	–
Loss on investments in investment partnerships	127	142
Loss on retirement of non-current assets	126	256
Loss on abandonment of non-current assets	66	88
Product recall-related expenses	–	310
Other	320	361
Total non-operating expenses	1,982	1,360
Ordinary profit	10,869	11,056
Extraordinary income		
Gain on change in equity	148	39
Gain on sale of investment securities	88	980
Total extraordinary income	237	1,020
Extraordinary losses		
Business restructuring expenses	377	–
Loss on valuation of investment securities	–	225
Total extraordinary losses	377	225
Profit before income taxes	10,729	11,852
Income taxes - current	3,704	4,851
Income taxes - deferred	(278)	(769)
Total income taxes	3,425	4,081
Profit	7,303	7,770
Profit attributable to		
Profit attributable to owners of parent	7,268	7,719
Profit attributable to non-controlling interests	35	51

(Unit: ¥ million)

	Nine months ended September 30, 2025	Nine months ended September 30, 2026
Other comprehensive income		
Valuation difference on available-for-sale securities	2,300	3,268
Deferred gains or losses on hedges	(316)	(629)
Foreign currency translation adjustment	(2,966)	(611)
Remeasurements of defined benefit plans, net of tax	(361)	(551)
Share of other comprehensive income of entities accounted for using equity method	(180)	(665)
Total other comprehensive income	(1,524)	811
Comprehensive income	5,779	8,582
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	5,750	8,493
Comprehensive income attributable to non-controlling interests	28	88

(Segment Information, etc.)

[Segment Information]

I. Nine months ended September 30, 2025 (January 1, 2025- September 30, 2025)

1. Information on net sales and profit or losses by reportable segment

(Unit: ¥ million)

	Reportable segments							Reconciling items (Note 1)	Per quarterly consolidated financial statements (Note 2)
	Health and Food Business	Dairy Food Business	Nutritional Confectionery Business	Food Ingredients Business	Other Domestic Business	Overseas Business	Reportable segments		
Sales									
Revenue from contracts with customers	36,936	50,287	44,266	9,926	58,503	64,815	264,736	–	264,736
Other revenues	–	–	–	–	–	–	–	–	–
Revenues from external customers	36,936	50,287	44,266	9,926	58,503	64,815	264,736	–	264,736
Transactions with other segments	–	–	–	230	5,932	–	6,163	(6,163)	–
Net sales	36,936	50,287	44,266	10,156	64,436	64,815	270,899	(6,163)	264,736
Operating profit (loss)	(327)	(4,682)	2,275	1,671	841	7,232	7,010	2,010	9,020

(Notes)

1. The adjusted amount of ¥2,010 million in segment profit or loss includes ¥1,374 million for the elimination of intersegment transactions and other adjustment amounts of ¥635 million in companywide expenses not allocated to any reporting segment.
2. The total amount for segment profit or loss is adjusted based on the operating profit or loss recorded for quarterly consolidated financial statements.

2. Impairment losses on fixed assets and information concerning goodwill, etc., for each reporting segment.

Not applicable.

II. Nine months ended September 30, 2026 (January 1, 2026- September 30, 2026)

1. Information on net sales and profit or losses by reportable segment

(Unit: ¥ million)

	Reportable segments							Reconciling items (Note 1)	Per quarterly consolidated financial statements (Note 2)
	Health and Food Business	Dairy Food Business	Nutritional Confectionery Business	Food Ingredients Business	Other Domestic Business	Overseas Business	Reportable segments		
Sales									
Revenue from contracts with customers	35,728	50,661	44,555	9,766	58,667	81,628	281,008	–	281,008
Other revenues	–	–	–	–	–	–	–	–	–
Revenues from external customers	35,728	50,661	44,555	9,766	58,667	81,628	281,008	–	281,008
Transactions with other segments	–	–	–	215	5,331	–	5,547	(5,547)	–
Net sales	35,728	50,661	44,555	9,981	63,999	81,628	286,556	(5,547)	281,008
Operating profit (loss)	(829)	(5,030)	1,088	1,853	521	10,527	8,130	116	8,246

(Notes)

1. The adjusted amount of ¥116 million in segment profit or loss includes ¥1,875 million for the elimination of intersegment transactions and other adjustment amounts of (¥1,758) million in companywide expenses not allocated to any reporting segment.
2. The total amount for segment profit or loss is adjusted based on the operating profit or loss recorded for quarterly consolidated financial statements.

2. Impairment losses on fixed assets and information concerning goodwill, etc., for each reporting segment.

Not applicable.

Supplementary Information

for the Nine Months Ended September 30, 2026 (Q3 FY2026)

Ezaki Glico Co., Ltd.

Consolidated results of operations (Cumulative)

*Amounts less than one million yen, one million CNY and one million USD are each rounded down.

(1) Status of Net Sales and Profit

Unit:1 million yen

	FYE Dec. '25 (Jan. to Sep.)	FYE Dec. '26 (Jan. to Sep.)	Change from previous period	
			Amount	%
Net sales	264,736	281,008	16,272	6.1
Operating profit	9,020	8,246	(774)	(8.6)
Ordinary profit	10,869	11,056	187	1.7
Profit	7,268	7,719	450	6.2

(2)Status of Operating Profit

Unit:1 million yen

	FYE Dec. '25		FYE Dec. '26	
	(Jan. to Sep.)	%	(Jan. to Sep.)	%
Net sales	264,736	100.0	281,008	100.0
Cost of sales	164,867	62.3	175,864	62.6
Gross profit	99,868	37.7	105,144	37.4
Freight and charges	22,324	8.4	22,083	7.9
Promotion expenses	9,461	3.6	11,664	4.2
Advertising expenses	10,959	4.1	11,100	4.0
Salaries and benefits	26,871	10.2	28,389	10.1
Expenses and depreciation	21,231	8.0	23,658	8.4
Total	90,847	34.3	96,897	34.5
Operating profit	9,020	3.4	8,246	2.9

Factors behind change in operating profit	vs FYE Dec. '25(Jan. to Sep.)	
		Of which, is domestic
(1) Change due to increase/decrease in net sales	7,041	(214)
(2) Change due to increase/decrease in raw materials prices	(6,455)	(4,841)
(3) Change due to increase/decrease from other changes in cost of sales *	3,315	1,304
(4) Change due to fluctuation in freight and charges ratio	1,613	751
(5) Change due to increase/decrease in sales promotion expenses / advertising expenses	(2,344)	747
(6) Change due to increase/decrease in SG&A expenses	(3,945)	(1,816)
Total	(774)	(4,068)

*Including fluctuation in composition of sales product varieties and other

(3) Status of Net Sales by Segment

Unit:1 million yen

		FYE Dec. '25 (Jan. to Sep.)	FYE Dec. '26 (Jan. to Sep.)	Change from previous period	
				Amount	%
Health and Food Business	Health	11,202	12,260	1,058	9.4
	Ice cream	16,548	14,853	(1,695)	(10.2)
	Other	9,185	8,614	(570)	(6.2)
	Total	36,936	35,728	(1,207)	(3.3)
Dairy Business	Yoghurt	6,570	5,857	(712)	(10.8)
	Ice cream	24,421	25,151	729	3.0
	Other	19,295	19,652	357	1.9
	Total	50,287	50,661	373	0.7
Nutritional Confectionery Business	Chocolate	23,289	23,433	143	0.6
	Cookies	17,228	17,467	239	1.4
	Other	3,748	3,654	(93)	(2.5)
	Total	44,266	44,555	289	0.7
Food Ingredients Business		9,926	9,766	(160)	(1.6)
Other Domestic Business		58,503	58,667	163	0.3
Overseas Business		64,815	81,628	16,813	25.9
Total		264,736	281,008	16,272	6.1

(4)Status of Operating Profit or Loss by Segment

Unit:1 million yen

	FYE Dec. '25 (Jan. to Sep.)	FYE Dec. '26 (Jan. to Sep.)	Change from previous period	
			Amount	%
Health and Food Business	(327)	(829)	(501)	-
Dairy Business	(4,682)	(5,030)	(347)	-
Nutritional Confectionery Business	2,275	1,088	(1,186)	(52.2)
Food Ingredients Business	1,671	1,853	182	10.9
Other Domestic Business	841	521	(320)	(38.0)
Overseas Business	7,232	10,527	3,294	45.5
Adjustment	2,010	116	(1,894)	(94.2)
Total	9,020	8,246	(774)	(8.6)

(5)Status of overseas Business: Region-Specific Net Sales and Operating Income

*The following figures are based on management accounting and differ from the figures in the consolidated financial statements. Geographic segment also differs from those in the figures in the consolidated financial statements.

◆China

Unit: 1 million CNY

	FYE Dec. '25 (Jan. to Sep.)	FYE Dec. '26 (Jan. to Sep.)	Change from previous period	
			Amount	%
Net sales	1,624	2,135	511	31.5
Operating profit	256	413	157	61.3

◆ASEAN

Unit: 1 million USD

	FYE Dec. '25 (Jan. to Sep.)	FYE Dec. '26 (Jan. to Sep.)	Change from previous period	
			Amount	%
Net sales	97	102	4	5.0
Operating profit	(1)	(3)	(1)	-

*Actual results for the Q3 of the fiscal year ended December 31, 2025 have been replaced by the average rate for the Q3 of the fiscal year ended December 31, 2026.

◆U.S.A.

Unit: 1 million USD

	FYE Dec. '25 (Jan. to Sep.)	FYE Dec. '26 (Jan. to Sep.)	Change from previous period	
			Amount	%
Net sales	78	67	(10)	(12.9)
Operating profit	17	13	(3)	(19.7)

*The figures for the U.S.A. are on a consolidated basis.